ArticleAntimicrobial agents and chemotherapy2017
Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam.
Abstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Clinical, microbiological, and molecular characteristics, outcomes, and risk factors for mortality of patients with Stenotrophomonas maltophilia bloodstream infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Multipathogen antimicrobial resistance in a Romanian tertiary-care hospital: a retrospective antibiogram analysis, January-July 2025.Journal of medicine and life · 2026Article
- Ceftazidime-avibactam and aztreonam as a therapeutic alternative in two episodes of bacteremia due to Stenotrophomonas maltophilia after allogeneic hematopoietic stem cell transplantation: case report.Revista peruana de medicina experimental y salud publica · 2026Article
- Genomic phylogeny, taxonomic classification, genetic landscape, and antibiotic resistance of clinicalFrontiers in microbiology · 2026Article
- Successful dual therapy of aztreonam and ceftazidime-avibactam for multidrug-resistantThe Journal of international medical research · 2025Article
- Classification and applicability of new beta-lactamase inhibitors.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025Review
- Aztreonam plus ceftazidime-avibactam for post-neurosurgical meningitis due toAntimicrobial agents and chemotherapy · 2025Article
- Ceftazidime retainsmSphere · 2025Article
- Therapeutic challenges in managingFrontiers in cellular and infection microbiology · 2025Review
- Management of infection and ocular complications in pediatric SJS/TEN-like acute graft-versus-host disease: a clinical case study and literature review.Frontiers in immunology · 2025Review
- Multicenter evaluation of activity of aztreonam in combination with avibactam, relebactam, and vaborbactam against metallo-β-lactamase-producing carbapenem-resistant gram-negative bacilli.Antimicrobial agents and chemotherapy · 2024Article
- Deciphering the Coevolutionary Dynamics of L2 β-Lactamases via Deep Learning.Journal of chemical information and modeling · 2024Article
- Article
- Characterization of a Novel Pathogen in Immunocompromised Patients:Open forum infectious diseases · 2023Article
- Epidemiology, Mechanisms of Resistance and Treatment Algorithm for Infections Due to Carbapenem-Resistant Gram-Negative Bacteria: An Expert Panel Opinion.Antibiotics (Basel, Switzerland) · 2022Review
- Clinical challenges treatingJAC-antimicrobial resistance · 2022Review
- Review
- Last resort beta-lactam antibiotics for treatment of New-Delhi Metallo-Beta-Lactamase producing Enterobacterales and other Difficult-to-Treat Resistance in Gram-negative bacteria: A real-life study.Frontiers in cellular and infection microbiology · 2022Observational
- Antimicrobial Treatment Strategies forAntibiotics (Basel, Switzerland) · 2021Review
- Stenotrophomonas maltophilia Susceptibility Testing Challenges and Strategies.Journal of clinical microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Maria F MojicaDepartment of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Krisztina M Papp-WallaceDepartment of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Magdalena A TaracilaResearch Service, Louis Stokes Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Melissa D BarnesResearch Service, Louis Stokes Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Joseph D RutterResearch Service, Louis Stokes Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Michael R JacobsDepartment of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
John J LiPumaDepartment of Pediatrics and Communicable Disease, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Thomas J WalshTransplantation-Oncology Infectious Diseases Program, Weill Cornell Medical Center, New York, New York, USA.
Alejandro J VilaInstituto de Biología Molecular y Celular de Rosario (IBR, CONICET-UNR), Rosario, Argentina.
Robert A BonomoDepartment of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA Robert.Bonomo@va.gov.
Funding
Understanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6MUnderstanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9MA Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4MMolecular Epidemiology of Carbapenem-Resistant Klebsiella pneumoniaeR21AI114508 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., VAN DUIN, DAVID · 2015 to 2016
$445kThe Continuing Challenge of Carbapenemases in K. pneumoniae: KPC-2 & NDM-1I01BX001974 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI BONOMO, ROBERT A. · 2013 to 2024
–Targeting Burkholderial β-lactamases: Structure, function, and regulationI01BX002872 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI DONSKEY, CURTIS, PAPP-WALLACE, KRISZTINA MARGARET · 2016 to 2023
–BLRD VA I01 BX001974BLRD VA I01 BX002872NIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI072219NIAID NIH HHS R01 AI100560NIAID NIH HHS R21 AI114508
Abstract
PubMed holds no abstract for this paper.
Indexed as
Anti-Bacterial AgentsAzabicyclo CompoundsAztreonambeta-Lactamase Inhibitorsbeta-LactamasesDrug CombinationsDrug Resistance, Multiple, BacterialGram-Negative Bacterial InfectionsHumansMicrobial Sensitivity TestsStenotrophomonas maltophiliaAnti-Bacterial AgentsavibactamAzabicyclo CompoundsAztreonambeta-Lactamase Inhibitorsbeta-lactamase L2beta-LactamasesDrug CombinationsavibactamaztreonamS. maltophilia
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.